---
title: "KalVista Pharmaceuticals Inc. to Participate in Fireside Chat at Cantor Global Healthcare Conference 2025"
description: "KalVista Pharmaceuticals Inc. (Nasdaq: KALV) will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 3, 2025, at 10:55 a.m. ET. A live webcast will be availabl"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254789048.md"
published_at: "2025-08-27T11:00:29.000Z"
---

# KalVista Pharmaceuticals Inc. to Participate in Fireside Chat at Cantor Global Healthcare Conference 2025

> KalVista Pharmaceuticals Inc. (Nasdaq: KALV) will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 3, 2025, at 10:55 a.m. ET. A live webcast will be available on the company's website, with an audio archive accessible for 30 days after the event.

KalVista Pharmaceuticals Inc. (Nasdaq: KALV) has announced its participation in a fireside chat at the Cantor Global Healthcare Conference 2025. The event is scheduled for Wednesday, September 3, 2025, at 10:55 a.m. ET. A live webcast of the presentation will be accessible on the company’s website, with an audio archive available for 30 days post-event. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250827892054) on August 27, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [KALV.US - KalVista Pharma](https://longbridge.com/en/quote/KALV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock | KalVista Pharmaceuticals CEO Benjamin Palleiko sold 3,354 shares at $15.70 each, totaling $52,657.80, reducing his owner | [Link](https://longbridge.com/en/news/275978075.md) |
| KalVista Pharmaceuticals Grants Stock Options to New Employees | KalVista Pharmaceuticals Inc. has granted stock options to six new employees, allowing them to purchase 96,750 shares of | [Link](https://longbridge.com/en/news/274650500.md) |
| Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV | Emerald Mutual Fund Advisers Trust increased its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 19.4% in Q3, o | [Link](https://longbridge.com/en/news/273494054.md) |
| KalVista reports $49M in 2025 Ekterly revenue, shares rise | KalVista Pharmaceuticals reported $49 million in revenue from Ekterly for 2025, with Q4 net product revenue at $35 milli | [Link](https://longbridge.com/en/news/272075883.md) |
| KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch | KalVista Pharmaceuticals Inc. reported approximately $35 million in global net product revenue for EKTERLY® in Q4 2025,  | [Link](https://longbridge.com/en/news/271983499.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.